JS-FMD: FIBROMUSCULAR DYSPLASIA IN ASIA: A DISEASE TO (RE)DISCOVER

Abstract

The International Consensus on Fibromuscular Dysplasia (FMD) (Gornik, Persu et al. J Hypertens. 2019;37:229–252; Vasc Med. 2019;24:164–189) provided a comprehensive summary of the clinical history, diagnosis and management of FMD. However, the authors admitted that most of current knowledge on FMD has been acquired in patients of Caucasian descent. Accordingly, they expressed their commitment to include a higher proportion of patients of non-white ethnicities in existing registries. Along these lines, the European International FMD Registry and Initiative (FEIRI, coord. A. Persu, Brussels) has established collaborations with centres from Japan and China and begun to enrol patients from these countries. The 2022 meeting of the International Society of Hypertension in Kyoto is a unique opportunity to further develop the Japanese FMD initiative (coord. Kan Zen, Kyoto), the Chinese FMD initiative (coord. Jiguang Wang, Shanghai) and potentially initiatives in other Asian countries. This implies also raising awareness of Asian experts on FMD and identifying the specificities of FMD in Asia. The objectives of the current session are: (1) to summarize the key messages of the international FMD Consensus; (2) to present preliminary data obtained in patients from Asian vs. Caucasian descent enrolled in the FEIRI registry; (3) to present current experience on the characteristics, diagnosis and management of FMD in centres from Japan (Kyoto, Osaka and Tokyo) and China (Shanghai); (4) to emphasize the specific challenges raised by FMD in Asia, particularly the differential diagnosis with Takayasu disease; (5) to open a debate with specialists of FMD in Japan and abroad, to expand the Japanese FMD initiative and to initiate new national initiatives on FMD in Asia, in collaboration with FEIRI.